Genital warts (GWs) are common, with about 5% to 10% of people having at least one
episode in their lifetime. They develop about 2–3 months after infection with human …

Introduction Since 2007, many countries have implemented national human papillomavirus
(HPV) vaccination programs with the quadrivalent HPV (4HPV) vaccine that has been …

Background The quadrivalent human papillomavirus (HPV) vaccine has been assumed to
give protection against genital warts (GW) as well as cervical cancer. Our main question was …

Abstract Background In 2009, Norway initiated routine quadrivalent HPV (qHPV) vaccination
for girls at 12–13 years of age to protect against virus types causing cervical cancer …

Background To assess the impact of a quadrivalent human papillomavirus vaccine (4HPV)
in women at increased risk of genital warts (GWs) acquisition. Methods The study was …

Abstract Background In 2009, both Norway and Denmark initiated routine quadrivalent
human papillomavirus vaccination (qHPV) for 12-year-old girls; however, Denmark also …

Background Increasing evidence suggests that 1-dose human papillomavirus (HPV)
vaccination may protect significantly against HPV-related disease. We provide nationwide …

Background For several decades, diagnoses of genital warts at genitourinary medicine
(GUM) clinics in England had been increasing. In 2008, a national human papillomavirus …

Background. More than 90% of genital warts (GW) cases are caused by human
papillomavirus (HPV) types 6 and 11. The introduction of HPV vaccines necessitates the …

The aim was to compare the epidemiological and economic impact of 16/18 bivalent and
6/11/16/18 quadrivalent HPV vaccination in France, considering differences in licensed …